Enveric Biosciences announces 1-for-15 reverse stock split effective Jan 27, 2025

Enveric Biosciences, Inc.

Shareholders approved reverse split at a special meeting on Jan 17, 2025; ratio range 1:10 to 1:100.
Board set ratio at 1-for-15; outstanding shares to reduce from ~10.4M to ~692,580.
No fractional shares; rounding up to next whole number; authorized shares remain 100M.
Trading symbol ENVB unchanged; new CUSIP 29405E 406; adjusted trading begins Jan 27.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Enveric Biosciences, Inc.: Filed a Certificate of Amendment to effect a 1-for-15 reverse stock split of common stock (effective 2025-01-27).

Change: charter amendment
Effective: 2025-01-27

Exact text from the filing

On January 17, 2025, Enveric Biosciences, Inc. (the “Company”) filed a Certificate of Amendment of Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-15 reverse stock split of the shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), either issued and outstanding or held by the Company as treasury stock, effective as of 8:00 a.m. (New York time) on January 27, 2025 (the “Reverse Stock Split”).

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-003091

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.